{'fraction_non_alphanumeric': 0.030252100840336135, 'fraction_numerical': 0.0, 'mean_word_length': 5.408602150537634, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical outcomes in real‐world patients with bifurcation lesions receiving Xience V everolimus‐eluting stents: Four‐year results from the Xience V USA study

The Xience V USA Study demonstrated safety and efficacy of the XIENCE V® everolimus‐eluting stent (EES) in a large, prospective study of a real‐world, unselected patient population. There is limited long‐term data regarding EES performance in high risk patients with bifurcation lesions (BIF). The objective of this analysis was to evaluate the long‐term safety and effectiveness of EES in patients with BIF from the XIENCE V USA study.